Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according...
Saved in:
| Published in | Journal of clinical oncology Vol. 29; no. 2; pp. 200 - 207 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Alexandria, VA
American Society of Clinical Oncology
10.01.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0732-183X 1527-7755 1527-7755 |
| DOI | 10.1200/JCO.2010.30.0368 |
Cover
| Abstract | Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications.
Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined.
The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL.
The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use. |
|---|---|
| AbstractList | Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications.
Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined.
The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL.
The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use. PURPOSE: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications. PATIENTS AND METHODS: Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined. RESULTS: The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL. CONCLUSION: The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use. Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications.PURPOSEPatients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify patients according to survival. This study compares some of those algorithms and also proposes some modifications.Two-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined.PATIENTS AND METHODSTwo-hundred and sixty-two cases of de novo DLBCL treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy were examined.The Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL.RESULTSThe Choi algorithm and Hans algorithm had high concordance with the microarray results. Modifications of the Choi and Hans algorithms for ease of use still retained high concordance with the microarray results. Although the Nyman and Muris algorithms had high concordance with the microarray results, each had a low value for either sensitivity or specificity. The use of LMO2 alone showed the lowest concordance with the microarray results. A new algorithm (Tally) using a combination of antibodies, but without regard to the order of examination, showed the greatest concordance with microarray results. All of the algorithms divided patients into groups with significantly different overall and event-free survivals, but with different hazard ratios. With the exception of the Nyman algorithm, this survival prediction was independent of the International Prognostic Index. Although the Muris algorithm had prognostic significance, it misclassified a large number of cases with activated B-cell type DLBCL.The Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use.CONCLUSIONThe Tally algorithm showed the best concordance with the microarray data while maintaining prognostic significance and ease of use. |
| Author | Lynette M. Smith Jan Delabie Rita M. Braziel Dennis D. Weisenburger Elias Campo Georg Lenz Andreas Rosenwald Paul N. Meyer Timothy C. Greiner Randy D. Gascoyne German Ott Julie M. Vose Louis M. Staudt Kai Fu Wing C. Chan |
| Author_xml | – sequence: 1 givenname: Paul N. surname: Meyer fullname: Meyer, Paul N. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 2 givenname: Kai surname: Fu fullname: Fu, Kai organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 3 givenname: Timothy C. surname: Greiner fullname: Greiner, Timothy C. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 4 givenname: Lynette M. surname: Smith fullname: Smith, Lynette M. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 5 givenname: Jan surname: Delabie fullname: Delabie, Jan organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 6 givenname: Randy D. surname: Gascoyne fullname: Gascoyne, Randy D. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 7 givenname: German surname: Ott fullname: Ott, German organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 8 givenname: Andreas surname: Rosenwald fullname: Rosenwald, Andreas organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 9 givenname: Rita M. surname: Braziel fullname: Braziel, Rita M. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 10 givenname: Elias surname: Campo fullname: Campo, Elias organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 11 givenname: Julie M. surname: Vose fullname: Vose, Julie M. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 12 givenname: Georg surname: Lenz fullname: Lenz, Georg organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 13 givenname: Louis M. surname: Staudt fullname: Staudt, Louis M. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 14 givenname: Wing C. surname: Chan fullname: Chan, Wing C. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research – sequence: 15 givenname: Dennis D. surname: Weisenburger fullname: Weisenburger, Dennis D. organization: From the University of Nebraska Medical Center, Omaha, NE; Rikshospitalet-Radiumhospitalet Medical Center, University of Oslo, Oslo, Norway; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Robert-Bosch-Krankenhaus, Stuttgart; University of Würzburg, Würzburg; Charité–Universitätsmedizin Berlin, Berlin, Germany; Oregon Health and Science University, Portland, OR; University of Barcelona, Barcelona, Spain; and Division of Cancer Treatment and Diagnosis, Center for Cancer Research |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23746719$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21135273$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhS1URKeFPSvkDYJNBj_z2CCV4VU0aCoogp3l2E7iKokH2xnof-BH4zBDeSy6sq78natzdM8JOBrdaAB4iNESE4SevVttlgSliaIlonl5BywwJ0VWFJwfgQUqKMlwSb8cg5MQrhDCrKT8HjgmGNPE0QX4cT4M0-g6G6JTnRmskj18b2LndICN8_DCG21VtGMLV6bvoWvgxtvWjlCOGn6c_M7ukiTNFzJaM8YAP9vYwZe2aaZg4Fr61sAX2S_x-nrYdm6Q8NIbGY3eox9snL7bQdb3wd1G9sE8OLyn4NPrV5ert9l68-Z8dbbOFGN5zKqi1kZzQupcIaI4YgXjlJZa1bXmEpGac5o3vDQ1Y4TROtemoCVqOEkjlvQUPN_v3U71YLRKrr3sxdYnE_5aOGnFvz-j7UTrdoIiXpKCpwVPDgu8-zqZEMVgg0oJ5WjcFERJSIVIzmby6a0kRhVllJc5Suijv13d2Pl9rAQ8PgAypDM1Xo7Khj8cLVhe4CpxaM8p70LwprlBMBJzb0TqjZh7kwKJuTdJkv8nUTame7o5v-1vEx48dbbtvllvRBhk36cIRFwpRypBkgDRn8Ma1Gc |
| CitedBy_id | crossref_primary_10_1007_s00277_024_05880_z crossref_primary_10_1016_j_cancergen_2013_07_003 crossref_primary_10_1038_s41375_019_0509_6 crossref_primary_10_1007_s12254_016_0290_4 crossref_primary_10_1007_s00428_016_2041_7 crossref_primary_10_1053_j_seminhematol_2015_01_006 crossref_primary_10_1182_bloodadvances_2023010402 crossref_primary_10_1038_leu_2012_83 crossref_primary_10_1053_j_seminhematol_2015_01_001 crossref_primary_10_1080_10428194_2018_1512711 crossref_primary_10_1016_j_clml_2017_10_007 crossref_primary_10_1186_1746_1596_6_77 crossref_primary_10_3233_TUB_211510 crossref_primary_10_14694_EdBook_AM_2015_35_e458 crossref_primary_10_1002_ajh_23658 crossref_primary_10_2147_CMAR_S345745 crossref_primary_10_3390_cancers13133352 crossref_primary_10_1016_j_pathol_2023_10_020 crossref_primary_10_1182_blood_2013_09_524108 crossref_primary_10_1200_JCO_2016_70_3660 crossref_primary_10_3390_cancers16122170 crossref_primary_10_1016_j_leukres_2013_01_002 crossref_primary_10_1182_blood_2013_06_508937 crossref_primary_10_1038_leu_2017_222 crossref_primary_10_3109_10428194_2013_790968 crossref_primary_10_1016_j_annpat_2012_07_003 crossref_primary_10_1016_j_clml_2021_07_017 crossref_primary_10_1182_blood_2010_11_321554 crossref_primary_10_4132_jptm_2017_04_09 crossref_primary_10_1200_JCO_2011_35_4423 crossref_primary_10_1111_bjh_13116 crossref_primary_10_1158_1078_0432_CCR_13_1482 crossref_primary_10_1097_PAP_0000000000000065 crossref_primary_10_1038_modpathol_2012_141 crossref_primary_10_1002_jha2_457 crossref_primary_10_1007_s00277_014_2116_y crossref_primary_10_3109_10428194_2013_784967 crossref_primary_10_30841_2307_5112_5_2018_165327 crossref_primary_10_1177_20406207211013987 crossref_primary_10_3892_mmr_2016_4899 crossref_primary_10_7759_cureus_21147 crossref_primary_10_1097_PAI_0000000000000335 crossref_primary_10_1007_s00428_023_03644_0 crossref_primary_10_1007_s12308_014_0220_5 crossref_primary_10_1097_PAI_0000000000000696 crossref_primary_10_1080_10428194_2017_1410884 crossref_primary_10_1016_j_leukres_2021_106513 crossref_primary_10_18632_oncotarget_12363 crossref_primary_10_1080_10428194_2017_1422863 crossref_primary_10_1007_s00277_016_2794_8 crossref_primary_10_1016_j_jmoldx_2020_11_013 crossref_primary_10_1016_j_path_2015_09_008 crossref_primary_10_1101_mcs_a001719 crossref_primary_10_1002_dc_22819 crossref_primary_10_1002_hon_2407 crossref_primary_10_1182_bloodadvances_2022007006 crossref_primary_10_1002_hon_2090 crossref_primary_10_1016_j_anndiagpath_2016_05_005 crossref_primary_10_1038_modpathol_2016_130 crossref_primary_10_47360_1995_4484_2024_575_581 crossref_primary_10_1158_1078_0432_CCR_22_2483 crossref_primary_10_1038_leu_2013_224 crossref_primary_10_1182_asheducation_2015_1_618 crossref_primary_10_1016_j_beha_2012_01_009 crossref_primary_10_1182_blood_2019000779 crossref_primary_10_1182_blood_2012_10_460063 crossref_primary_10_1182_blood_2015_08_662635 crossref_primary_10_18632_oncotarget_15782 crossref_primary_10_3389_fgene_2022_1092678 crossref_primary_10_1093_annonc_mds621 crossref_primary_10_1007_s00277_014_2132_y crossref_primary_10_1111_bjh_17811 crossref_primary_10_1016_S1470_2045_13_70450_9 crossref_primary_10_3109_10428194_2013_813499 crossref_primary_10_1182_asheducation_V2012_1_402_3798516 crossref_primary_10_1634_theoncologist_2016_0103 crossref_primary_10_1182_asheducation_2015_1_605 crossref_primary_10_1200_JCO_2013_54_9493 crossref_primary_10_1038_leu_2012_284 crossref_primary_10_1053_j_seminhematol_2023_11_006 crossref_primary_10_3390_diagnostics13172775 crossref_primary_10_1182_blood_2013_08_518878 crossref_primary_10_1038_s41598_020_64212_z crossref_primary_10_1093_narcan_zcaa029 crossref_primary_10_1158_1078_0432_CCR_11_0267 crossref_primary_10_1007_s00262_016_1883_9 crossref_primary_10_1093_ajcp_aqw034 crossref_primary_10_1073_pnas_1305656110 crossref_primary_10_1093_jjco_hyac039 crossref_primary_10_1093_ajcp_aqad006 crossref_primary_10_1159_000497430 crossref_primary_10_1080_17474086_2019_1677152 crossref_primary_10_3109_10428194_2011_626882 crossref_primary_10_1182_bloodadvances_2019000989 crossref_primary_10_1111_bjh_12356 crossref_primary_10_1016_j_hoc_2016_07_005 crossref_primary_10_1007_s12672_023_00754_8 crossref_primary_10_1097_PAS_0000000000000319 crossref_primary_10_1182_blood_2012_10_461848 crossref_primary_10_1016_j_hoc_2016_07_001 crossref_primary_10_1080_17474086_2019_1660159 crossref_primary_10_1182_blood_2012_02_414441 crossref_primary_10_1016_S2352_3026_20_30120_4 crossref_primary_10_1158_1078_0432_CCR_14_0497 crossref_primary_10_2147_BLCTT_S407086 crossref_primary_10_1007_s00428_022_03466_6 crossref_primary_10_1158_2159_8290_CD_20_0174 crossref_primary_10_1016_j_humpath_2024_105630 crossref_primary_10_1038_srep12168 crossref_primary_10_3324_haematol_2019_236455 crossref_primary_10_1111_cas_16344 crossref_primary_10_33590_emjhematol_10313900 crossref_primary_10_1038_srep20465 crossref_primary_10_1186_s12885_017_3931_z crossref_primary_10_1016_j_leukres_2011_12_012 crossref_primary_10_1016_j_prp_2022_153804 crossref_primary_10_1111_ddg_13773_g crossref_primary_10_1200_JCO_2011_37_5733 crossref_primary_10_1016_j_blre_2017_12_001 crossref_primary_10_1111_bjh_12343 crossref_primary_10_1002_hon_2399 crossref_primary_10_3109_10428194_2012_738365 crossref_primary_10_12677_ACM_2024_142542 crossref_primary_10_1002_ajh_26835 crossref_primary_10_1016_j_beha_2018_07_003 crossref_primary_10_1038_bcj_2015_111 crossref_primary_10_5045_br_2013_48_4_266 crossref_primary_10_1111_bjh_14089 crossref_primary_10_1002_cncy_21626 crossref_primary_10_1016_j_pathol_2015_11_017 crossref_primary_10_1177_107327481201900306 crossref_primary_10_1182_blood_2013_11_536433 crossref_primary_10_1002_hon_2280 crossref_primary_10_1080_10428194_2023_2298705 crossref_primary_10_3109_10428194_2013_778407 crossref_primary_10_1371_journal_pone_0223260 crossref_primary_10_1182_blood_2020006338 crossref_primary_10_1016_j_critrevonc_2012_12_009 crossref_primary_10_1016_j_jmb_2018_06_016 crossref_primary_10_2217_ijh_2019_0010 crossref_primary_10_1073_pnas_1507459112 crossref_primary_10_1182_blood_2018_06_855502 crossref_primary_10_3960_jslrt_17029 crossref_primary_10_1309_AJCP3CP6VFZJYMTK crossref_primary_10_18632_oncotarget_9507 crossref_primary_10_1038_modpathol_2013_156 crossref_primary_10_1080_10428194_2017_1390230 crossref_primary_10_1002_cncy_21535 crossref_primary_10_1111_his_13832 crossref_primary_10_1186_s13045_015_0168_7 crossref_primary_10_1007_s00428_013_1519_9 crossref_primary_10_1093_narcan_zcae007 crossref_primary_10_1111_bjh_16494 crossref_primary_10_1186_s41231_020_00054_1 crossref_primary_10_1007_s11912_021_01155_2 crossref_primary_10_1111_ddg_13773 crossref_primary_10_1056_NEJMra2027612 crossref_primary_10_1002_hon_2178 crossref_primary_10_18632_oncotarget_16435 crossref_primary_10_1097_PAI_0000000000000107 crossref_primary_10_1038_modpathol_2012_119 crossref_primary_10_3390_ijms25063094 crossref_primary_10_1111_bjh_14744 crossref_primary_10_1093_annonc_mdv019 crossref_primary_10_1200_JCO_2017_73_2784 crossref_primary_10_1111_j_1440_1827_2011_02748_x crossref_primary_10_3889_oamjms_2023_11775 crossref_primary_10_1007_s12253_012_9585_x crossref_primary_10_1164_rccm_201303_0462OC crossref_primary_10_1182_asheducation_2011_1_330 crossref_primary_10_1182_bloodadvances_2023011408 crossref_primary_10_3390_cancers12040884 crossref_primary_10_1200_JCO_2014_60_2383 crossref_primary_10_1200_JCO_2011_41_0985 crossref_primary_10_1016_j_hoc_2019_03_001 crossref_primary_10_12688_f1000research_16755_1 crossref_primary_10_18632_oncotarget_12988 crossref_primary_10_5858_arpa_2014_0086_RA crossref_primary_10_5858_arpa_2016_0260_SA crossref_primary_10_1111_j_1365_2559_2012_04179_x crossref_primary_10_1016_j_path_2013_05_007 crossref_primary_10_1016_S1470_2045_14_70234_7 crossref_primary_10_1182_blood_2016_11_750174 crossref_primary_10_1177_09760016241302540 crossref_primary_10_1002_cyto_a_23919 crossref_primary_10_1016_j_jmoldx_2015_03_010 crossref_primary_10_1111_his_15350 crossref_primary_10_1182_asheducation_2011_1_506 crossref_primary_10_1080_10428194_2023_2234523 crossref_primary_10_1093_jnen_nlx083 crossref_primary_10_1186_s13045_017_0438_7 crossref_primary_10_4103_ijpm_ijpm_343_21 crossref_primary_10_1182_blood_2018889931 crossref_primary_10_1007_s11899_013_0169_y crossref_primary_10_1309_AJCPPHMZ6VHF0WQV crossref_primary_10_4251_wjgo_v4_i12_238 crossref_primary_10_1080_10428194_2018_1515940 crossref_primary_10_1111_bjh_13085 crossref_primary_10_1038_s41379_021_00962_z crossref_primary_10_1016_j_blre_2018_03_005 crossref_primary_10_1182_blood_2015_03_632430 crossref_primary_10_1007_s12254_019_0472_y crossref_primary_10_1371_journal_pone_0098169 crossref_primary_10_4103_jpi_jpi_14_18 crossref_primary_10_1016_j_jfma_2016_09_006 crossref_primary_10_1097_PAI_0000000000000843 crossref_primary_10_3390_cancers15102753 crossref_primary_10_1007_s00277_015_2552_3 crossref_primary_10_1080_15513815_2022_2120786 crossref_primary_10_1002_ajh_25666 crossref_primary_10_1182_bloodadvances_2020001949 crossref_primary_10_1016_j_pathol_2017_09_006 crossref_primary_10_1111_bcp_14611 crossref_primary_10_1016_j_humpath_2014_06_005 crossref_primary_10_1002_cncr_29113 crossref_primary_10_1182_blood_2011_04_345256 crossref_primary_10_1097_PAS_0000000000001830 crossref_primary_10_1093_annonc_mdy113 crossref_primary_10_1093_annonc_mdx022 crossref_primary_10_1007_s10555_015_9581_1 crossref_primary_10_1016_j_clml_2011_07_003 crossref_primary_10_4161_cbt_13_1_18438 crossref_primary_10_1016_j_amjms_2017_02_002 crossref_primary_10_1182_bloodadvances_2020003698 crossref_primary_10_1016_j_path_2019_03_005 crossref_primary_10_3390_cimb46070420 crossref_primary_10_3892_ol_2019_9900 crossref_primary_10_3390_cells10030675 crossref_primary_10_1016_j_modpat_2022_100007 crossref_primary_10_1016_j_anndiagpath_2016_07_008 crossref_primary_10_3390_cancers13164049 crossref_primary_10_1007_s12288_019_01248_w crossref_primary_10_1016_j_prp_2017_02_012 crossref_primary_10_1002_hon_2805 crossref_primary_10_1111_his_12706 crossref_primary_10_1007_s00277_014_2256_0 crossref_primary_10_1038_cgt_2015_39 crossref_primary_10_1038_s41408_019_0208_6 crossref_primary_10_1111_hae_12741 crossref_primary_10_1182_blood_2014_05_577189 crossref_primary_10_1038_modpathol_2012_52 crossref_primary_10_1097_PPO_0000000000000014 crossref_primary_10_1097_PPO_0b013e31826aee97 crossref_primary_10_12688_f1000research_134946_2 crossref_primary_10_1038_modpathol_2016_92 crossref_primary_10_12688_f1000research_134946_3 crossref_primary_10_2147_OTT_S326632 crossref_primary_10_3390_cancers14061453 crossref_primary_10_1182_blood_2012_05_428466 crossref_primary_10_12688_f1000research_134946_1 crossref_primary_10_1097_PAI_0b013e31825d550a crossref_primary_10_1200_JCO_2010_32_8385 crossref_primary_10_1007_s12288_020_01322_8 crossref_primary_10_3109_10428194_2013_866665 crossref_primary_10_3109_10428194_2011_600482 crossref_primary_10_1111_bjh_12763 crossref_primary_10_18632_oncotarget_7495 crossref_primary_10_2217_fon_2021_0370 crossref_primary_10_1200_JCO_2014_58_9846 crossref_primary_10_1186_s12967_018_1537_0 crossref_primary_10_1007_s00277_018_3442_2 crossref_primary_10_1038_s41375_023_02120_7 crossref_primary_10_1136_jclinpath_2017_204548 crossref_primary_10_1093_jnci_djw257 crossref_primary_10_1016_S2352_3026_14_70016_X crossref_primary_10_1002_cncr_32866 crossref_primary_10_1097_PAS_0b013e31823ea106 crossref_primary_10_2217_fon_12_40 crossref_primary_10_1586_17474086_2016_1146584 crossref_primary_10_3389_fonc_2020_00329 crossref_primary_10_1111_bjh_14136 crossref_primary_10_1200_JCO_2011_38_5229 crossref_primary_10_25259_SNI_314_2020 crossref_primary_10_1097_PAS_0000000000000836 crossref_primary_10_1016_j_anndiagpath_2012_01_004 crossref_primary_10_1093_annonc_mdw419 crossref_primary_10_1200_JCO_2014_57_7080 crossref_primary_10_1097_COC_0000000000000215 crossref_primary_10_1016_j_exphem_2014_07_263 crossref_primary_10_1111_cas_12812 crossref_primary_10_1111_ejh_13384 crossref_primary_10_1007_s00428_018_2367_4 crossref_primary_10_3389_fonc_2023_1221471 crossref_primary_10_5858_arpa_2015_0418_CP crossref_primary_10_1038_modpathol_2012_178 crossref_primary_10_1158_1078_0432_CCR_15_0253 crossref_primary_10_1016_j_cca_2018_07_015 crossref_primary_10_1016_j_jfma_2012_07_031 crossref_primary_10_3109_10428194_2013_824077 crossref_primary_10_1371_journal_pone_0057677 crossref_primary_10_1177_2040620711419001 crossref_primary_10_1111_aos_12189 crossref_primary_10_1097_PCR_0b013e3182523067 crossref_primary_10_18632_oncotarget_14182 crossref_primary_10_3892_ol_2016_5012 crossref_primary_10_1016_j_prp_2023_154973 crossref_primary_10_1158_0008_5472_CAN_12_3546 crossref_primary_10_1007_s12288_024_01933_5 crossref_primary_10_1084_jem_20141957 crossref_primary_10_1111_bjh_14009 crossref_primary_10_1097_MD_0000000000000353 crossref_primary_10_1002_hon_2312 crossref_primary_10_1371_journal_pone_0114398 crossref_primary_10_1016_j_ijbiomac_2025_139893 crossref_primary_10_1055_s_0041_1735392 crossref_primary_10_1200_JCO_2015_65_7171 crossref_primary_10_3960_jslrt_54_117 crossref_primary_10_3109_10428194_2014_982636 crossref_primary_10_1093_annonc_mdu109 crossref_primary_10_1634_theoncologist_2018_0361 crossref_primary_10_3904_kjim_2012_27_4_369 crossref_primary_10_1111_bjh_13273 crossref_primary_10_1002_ajh_22078 crossref_primary_10_1007_s12254_017_0367_8 crossref_primary_10_1080_14737159_2016_1235974 crossref_primary_10_1182_blood_2012_05_430389 crossref_primary_10_3109_10428194_2011_584254 crossref_primary_10_3389_fonc_2023_1224733 crossref_primary_10_34883_PI_2020_6_2_007 crossref_primary_10_1111_his_12223 crossref_primary_10_3109_10428194_2016_1169406 crossref_primary_10_1016_j_yexmp_2015_08_019 crossref_primary_10_1038_s41598_020_67738_4 crossref_primary_10_3390_hemato3030034 crossref_primary_10_1038_leu_2011_340 crossref_primary_10_1016_j_pathol_2020_12_003 crossref_primary_10_1200_EDBK_175437 crossref_primary_10_1016_S1413_8670_12_70278_7 crossref_primary_10_1038_s41379_020_0506_3 crossref_primary_10_1155_2012_464680 crossref_primary_10_1111_bjh_15446 crossref_primary_10_1016_j_blre_2016_06_003 crossref_primary_10_1093_jnen_nlz125 crossref_primary_10_1111_bjh_12172 crossref_primary_10_1016_j_clml_2014_05_002 crossref_primary_10_1097_PAP_0000000000000117 crossref_primary_10_2217_fon_15_144 crossref_primary_10_1093_neuonc_nov046 crossref_primary_10_1016_j_canlet_2020_07_032 crossref_primary_10_1016_j_ntm_2023_100002 crossref_primary_10_1016_j_leukres_2012_01_022 crossref_primary_10_1038_leu_2012_367 crossref_primary_10_1002_hon_2217 crossref_primary_10_1038_leu_2015_43 crossref_primary_10_1186_s12967_019_1951_y crossref_primary_10_1097_MOH_0b013e32834706ee crossref_primary_10_1080_10428194_2019_1706731 crossref_primary_10_1080_17474086_2017_1268046 crossref_primary_10_3390_cells12010196 crossref_primary_10_1182_blood_2010_12_322362 crossref_primary_10_3109_10428194_2015_1083563 crossref_primary_10_5858_arpa_2014_0451_CP crossref_primary_10_1080_10428194_2016_1228932 crossref_primary_10_1016_j_clml_2015_02_006 crossref_primary_10_1111_j_1365_2559_2012_04198_x crossref_primary_10_1007_s12185_018_2466_7 crossref_primary_10_3390_cancers12113305 crossref_primary_10_1016_j_soc_2019_08_009 crossref_primary_10_1182_bloodadvances_2019001201 crossref_primary_10_1634_theoncologist_2012_0218 crossref_primary_10_2169_naika_100_1765 crossref_primary_10_3390_cancers12010185 |
| Cites_doi | 10.1056/NEJMoa0802885 10.1200/JCO.2007.13.0690 10.1038/sj.onc.1210376 10.1073/pnas.1732008100 10.5858/2008-132-118-DLBL 10.1158/1078-0432.CCR-09-0113 10.1200/JCO.2007.13.1391 10.1182/blood-2003-05-1545 10.1182/blood-2009-01-199679 10.1182/blood-2006-09-047068 10.1002/path.1924 10.1200/JCO.2006.09.4490 10.1038/modpathol.2009.73 10.1200/JCO.2007.15.9277 10.1038/35000501 |
| ContentType | Journal Article |
| Copyright | 2015 INIST-CNRS 2010 by American Society of Clinical Oncology |
| Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2010 by American Society of Clinical Oncology |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 5PM |
| DOI | 10.1200/JCO.2010.30.0368 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE AIDS and Cancer Research Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| EndPage | 207 |
| ExternalDocumentID | PMC3058275 21135273 23746719 10_1200_JCO_2010_30_0368 jco29_2_200 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA036727 – fundername: NCI NIH HHS grantid: U01-CA114778-01 – fundername: NCI NIH HHS grantid: U01 CA114778 – fundername: NCI NIH HHS grantid: CA36727 – fundername: National Institutes of Health |
| GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 --- .55 0R~ 18M AAYOK AAYXX ABBLC ABJNI ACGFO ACGUR AEGXH AI. AIAGR C45 CITATION F9R FBNNL HZ~ MJL QTD R1G RLZ TEORI TR2 VVN YFH YQY .GJ 08G 08P 29K 5VS 8WZ A6W AAKAS AAQOH AAQQT ADZCM ASPBG AVWKF AZFZN BYPQX D-I EX3 FEDTE HVGLF IPNFZ IQODW J5H N4W NTWIH RIG UHU WOQ WOW ZGI CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c446t-97bded522b6c02c504745338dcbbd5a02b5536f58eb44243b6de7380f524241a3 |
| ISSN | 0732-183X 1527-7755 |
| IngestDate | Thu Aug 21 14:05:20 EDT 2025 Fri Sep 05 02:56:44 EDT 2025 Thu Sep 04 23:21:42 EDT 2025 Mon Jul 21 06:02:53 EDT 2025 Mon Jul 21 09:17:21 EDT 2025 Tue Jul 01 01:11:25 EDT 2025 Thu Apr 24 22:54:34 EDT 2025 Tue Jan 05 20:16:28 EST 2021 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Antineoplastic agent Human Immunohistochemistry Cell survival Rituximab B cell neoplasm Malignant hemopathy Monoclonal antibody Method Non Hodgkin lymphoma Anatomic pathology Cancerology Treatment Lymphoproliferative syndrome Immunotherapy Diffuse large B cell lymphoma Cancer Cell origin |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c446t-97bded522b6c02c504745338dcbbd5a02b5536f58eb44243b6de7380f524241a3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 21135273 |
| PQID | 1093435860 |
| PQPubID | 23462 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3058275 proquest_miscellaneous_822902645 proquest_miscellaneous_1093435860 pubmed_primary_21135273 pascalfrancis_primary_23746719 crossref_primary_10_1200_JCO_2010_30_0368 crossref_citationtrail_10_1200_JCO_2010_30_0368 highwire_smallpub2_jco29_2_200 |
| ProviderPackageCode | RHI CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-01-10 |
| PublicationDateYYYYMMDD | 2011-01-10 |
| PublicationDate_xml | – month: 01 year: 2011 text: 2011-01-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | Alexandria, VA |
| PublicationPlace_xml | – name: Alexandria, VA – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2011 |
| Publisher | American Society of Clinical Oncology |
| Publisher_xml | – name: American Society of Clinical Oncology |
| References | B10 B11 B13 Hunt KE (B14) 2008; 132 B15 B16 Stein H (B12) 2008 B1 B2 B3 B4 B5 B6 B7 B8 B9 18086797 - J Clin Oncol. 2008 Jan 20;26(3):447-54 16400625 - J Pathol. 2006 Apr;208(5):714-23 12900505 - Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 17530014 - Oncogene. 2007 May 28;26(25):3603-13 14504078 - Blood. 2004 Jan 1;103(1):275-82 10676951 - Nature. 2000 Feb 3;403(6769):503-11 18662967 - J Clin Oncol. 2008 Oct 1;26(28):4587-94 19448593 - Mod Pathol. 2009 Aug;22(8):1094-101 17299093 - Blood. 2007 Jun 1;109(11):4930-5 19380866 - Blood. 2009 Jun 11;113(24):6069-76 18181663 - Arch Pathol Lab Med. 2008 Jan;132(1):118-24 18378569 - J Clin Oncol. 2008 Jun 1;26(16):2717-24 19038878 - N Engl J Med. 2008 Nov 27;359(22):2313-23 17327602 - J Clin Oncol. 2007 Mar 1;25(7):805-12 19706817 - Clin Cancer Res. 2009 Sep 1;15(17):5494-502 |
| References_xml | – ident: B2 doi: 10.1056/NEJMoa0802885 – ident: B6 doi: 10.1200/JCO.2007.13.0690 – ident: B13 doi: 10.1038/sj.onc.1210376 – ident: B10 doi: 10.1073/pnas.1732008100 – volume: 132 start-page: 118 year: 2008 ident: B14 publication-title: Arch Pathol Lab Med doi: 10.5858/2008-132-118-DLBL – ident: B4 doi: 10.1158/1078-0432.CCR-09-0113 – ident: B15 doi: 10.1200/JCO.2007.13.1391 – ident: B3 doi: 10.1182/blood-2003-05-1545 – start-page: 233 volume-title: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4) year: 2008 ident: B12 – ident: B16 doi: 10.1182/blood-2009-01-199679 – ident: B8 doi: 10.1182/blood-2006-09-047068 – ident: B5 doi: 10.1002/path.1924 – ident: B11 doi: 10.1200/JCO.2006.09.4490 – ident: B7 doi: 10.1038/modpathol.2009.73 – ident: B9 doi: 10.1200/JCO.2007.15.9277 – ident: B1 doi: 10.1038/35000501 – reference: 17327602 - J Clin Oncol. 2007 Mar 1;25(7):805-12 – reference: 10676951 - Nature. 2000 Feb 3;403(6769):503-11 – reference: 18086797 - J Clin Oncol. 2008 Jan 20;26(3):447-54 – reference: 18378569 - J Clin Oncol. 2008 Jun 1;26(16):2717-24 – reference: 18662967 - J Clin Oncol. 2008 Oct 1;26(28):4587-94 – reference: 16400625 - J Pathol. 2006 Apr;208(5):714-23 – reference: 17530014 - Oncogene. 2007 May 28;26(25):3603-13 – reference: 14504078 - Blood. 2004 Jan 1;103(1):275-82 – reference: 17299093 - Blood. 2007 Jun 1;109(11):4930-5 – reference: 19448593 - Mod Pathol. 2009 Aug;22(8):1094-101 – reference: 19706817 - Clin Cancer Res. 2009 Sep 1;15(17):5494-502 – reference: 19038878 - N Engl J Med. 2008 Nov 27;359(22):2313-23 – reference: 12900505 - Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 – reference: 18181663 - Arch Pathol Lab Med. 2008 Jan;132(1):118-24 – reference: 19380866 - Blood. 2009 Jun 11;113(24):6069-76 |
| SSID | ssj0014835 |
| Score | 2.5365543 |
| Snippet | Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray... PURPOSE: Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 200 |
| SubjectTerms | Algorithms Antibodies Antibodies, Monoclonal, Murine-Derived - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell lymphoma Biological and medical sciences Cell survival Cyclophosphamide Cyclophosphamide - administration & dosage Data processing Doxorubicin Doxorubicin - administration & dosage Hematologic and hematopoietic diseases Humans Immunohistochemistry Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphocytes B Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Medical sciences Original Reports Prednisone Prednisone - administration & dosage Rituximab Survival Rate Tumors Vincristine Vincristine - administration & dosage |
| Title | Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab |
| URI | http://jco.ascopubs.org/content/29/2/200.abstract https://www.ncbi.nlm.nih.gov/pubmed/21135273 https://www.proquest.com/docview/1093435860 https://www.proquest.com/docview/822902645 https://pubmed.ncbi.nlm.nih.gov/PMC3058275 |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF6FIiFeEJSj4agWCVVCqVt7vT7yCKGhoKSpUCryZu36EEaJjUiMCH-AF340M7u-UlJUeLESZ7N2Mp9nZ2a_mSHkhUikb8rIMlgM7iq3RAx6UFqG73oRS5iw7ESxLc7c0wv-fubMOp2fLdZSsZJH4Y-teSX_I1U4B3LFLNl_kGw9KZyA1yBfOIKE4XgtGb_D5I5clQwOq8T_sWoJraosIL8iwpQP3NrHGB0YhhPVCEsTNgtQE99U0Q2s1J-qXLePGJd9kyZJsYx7I6SJ914b6sujNQg-X4jeFO1MsFPV0A_pqvieLoS8wsqtMy_zLNyI4I_jtUYLchObDaFhoTkeaYsYlGYbuGoFdquw0GidIWWpDO1GTVQWiXQtXefZzADtMmsr5jIUkrb841LLmmZrwWa6be4fawHTba4HE03gs80jWK39Zt2r9vrPJsHwYjQKpiez6Q1yk3mehdzQt7OaKwQuo-7UWt1lud8NVzi-PP-mfVPVnEbKrVjCv53odinb_JnLtNyWnTO9S-6UoqOvNNrukU6c7ZJb45KCsUsOznWx8_UhnTa5e8tDekDPmzLo6_vk1xZ00hKdFNBJG3RSBBjNE6rRSQGdtEInhfcVOilCjpbopAqdVKOTVuikJTr10BqdD8jF8GQ6ODXK3h9GyLm7MvqejOIInAPphiYLHZN7HDwTPwqljBxhMuk4tps4fiw5Z9yWbhR7tm8mDuY7WcJ-SHayPIv3CAWj3pawUEkuIs6TWDght0wv8WCgAPu-S44riQVhWRgf-7PMA3SQGe72DiYByjiwzQBl3CUv62980UVh_jJ2vwJBsFyI-RxkzILPYc76AcMmsDBgAxr1jMzGVkBWv0ueV1gJQPfjhp7I4rxYInvEBnfHd2ESesUY1dABvB74mY80vJoLWJaN9Re7xNsAXj0AS89vfpKln1QJerASfOY5j69xa0_I7eaJf0p2Vl-L-BkY8iu5rx6y31Cr9x0 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immunohistochemical+Methods+for+Predicting+Cell+of+Origin+and+Survival+in+Patients+With+Diffuse+Large+B-Cell+Lymphoma+Treated+With+Rituximab&rft.jtitle=Journal+of+clinical+oncology&rft.au=Meyer%2C+Paul+N&rft.au=Fu%2C+Kai&rft.au=Greiner%2C+Timothy+C&rft.au=Smith%2C+Lynette+M&rft.date=2011-01-10&rft.issn=0732-183X&rft.volume=29&rft.issue=2&rft.spage=200&rft.epage=207&rft_id=info:doi/10.1200%2FJCO.2010.30.0368&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |